行情

GNMK

GNMK

GenMark诊断
NASDAQ

实时行情|Nasdaq Last Sale

4.160
+0.050
+1.22%
盘前 04:28 03/30 EDT
开盘
4.150
昨收
4.110
最高
4.275
最低
3.850
成交量
127.87万
成交额
--
52周最高
8.17
52周最低
3.360
市值
2.53亿
市盈率(TTM)
-5.0541
分时
5日
1月
3月
1年
5年

分析师评级

7位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测GNMK价格均价为9.75,最高价位11.00,最低价为8.00。

EPS

GNMK 新闻

更多
  • Genmark Diagnostics nabs BARDA contract to develop respiratory pathogen panel
  • seekingalpha · 6天前
  • GenMark Awarded BARDA Grant for the Development of ePlex® RP2 Panel
  • GlobeNewswire · 6天前
  • Is the Options Market Predicting a Spike in GenMark (GNMK) Stock?
  • Zacks · 6天前
  • Company News for Mar 23, 2020
  • Zacks · 6天前

所属板块

先进医疗设备和技术
-2.20%
医疗设备和用品
-1.86%

热门股票

代码
价格
涨跌幅

GNMK 简况

GenMark Diagnostics, Inc. is a molecular diagnostics company. The Company is focused on developing and commercializing multiplex molecular tests that aid in the diagnosis of complex medical conditions. It develops and commercializes multiplex molecular tests based on its eSensor electrochemical detection technology. It offers four Food and Drug Administration (FDA)-cleared diagnostic tests which run on its XT-8 instrument; its Respiratory Viral Panel; its Cystic Fibrosis Genotyping Test; its Warfarin Sensitivity Test, and its Thrombophilia Risk Test. It also offers a Hepatitis C (HCV) genotyping test and associated custom manufactured reagents, as well as a 2C19 Genotyping Test, versions of which are available for use with its XT-8 instrument for research use only (RUO). Its XT-8 and ePlex test cartridges utilize the combination of distinct electrodes and multiple signal probes to detect dozens of target biomarkers from a single sample, thereby enabling highly multiplexed testing.
展开

微牛提供GenMark Diagnostics, Inc(NASDAQ-GNMK)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的GNMK股票新闻,以帮助您做出投资决策。